Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JMT101 Combined With Afatinib in Advanced Esophageal Squamous Cell Carcinoma
NCT05164848Phase 1Unknown
- Sponsor
- Peking University
- Start
- Dec 2021
- Primary completion
- Oct 2023
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of becotatug in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Peking University. Primary endpoint: Incidence of Treatment-related Adverse Events, Safety and Tolerability at 2 years. Status: unknown.
02
Drugs
becotatug
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05164848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05164848.